Teuza: Nano Cell Is No Longer a Footnote, and the Question Is Whether It Is an Asset or a Funding Line
The main article already showed that Teuza's 2026 test sits at the cash layer. Nano Cell, now nearly level with Tyto at a $2.913 million holding value, offers real upside but also an active follow-on funding burden: revenue fell to $265 thousand, Teuza put in another $450 thousand during 2025 and $250 thousand after year-end, and a further $400 thousand option remains open through March 31, 2027.
Nano Cell Is No Longer a Footnote
The main article argued that Teuza's problem is no longer whether value still exists in the portfolio, but how much of that value can actually reach the cash layer. This follow-up isolates Nano Cell because by the end of 2025 it is no longer a side position. At a fair value of $2.913 million, it sits only $38 thousand below Tyto and is up by $500 thousand versus the end of 2024. In other words, the second asset in the portfolio has almost caught the first.
The problem is that this rise does not stand on its own. The same portfolio view that places Nano Cell almost next to Tyto also says another $250 thousand is expected to go into the company in the coming year. This is no longer just a fair-value line. It is an active capital-allocation layer. So the right question is not whether Nano Cell can become worth more. It is whether this value is starting to behave like an asset, or whether it still depends on repeated follow-on checks.
| Metric | Number | Why it matters |
|---|---|---|
| Fair value at year-end 2025 | $2.913 million | It is now almost level with Tyto, not a secondary holding |
| Gap versus Tyto | Only $38 thousand | The second anchor in the portfolio has nearly matched the first |
| Ownership stake | 16.4% basic, 12.5% fully diluted | A material holding, but not one that erases commercialization risk |
| Company value | $18 million | This is the number supporting the higher carrying mark |
| Expected investment in the coming year | $250 thousand | Even at year-end 2025 the story still clearly required more cash |
What matters most is that Nano Cell now sits exactly at the intersection between upside and follow-on funding. In Tyto, the core debate is how value is distributed through a complex capital structure. In Nano Cell, the issue is different: the mark has almost climbed into Tyto territory, but the path there ran once again through a financing round.
The Same Round Both Supports the Mark and Demands More Cash
This is where Nano Cell becomes a capital-discipline test. The carrying value of the holding at the end of 2025 does not rest on a separate valuation report. It rests on the latest financing round or last share transaction. That looks like a small technical detail, but it is the core of the thesis. When value is set through a round, it becomes hard to separate validation from dependence. The same event that lifts the carrying mark is also the event that asks for more money.
The chain itself is clear. At the start of 2022, Teuza put in $900 thousand in a $3 million round. At the end of 2022 and again in April 2023, it added another $550 thousand inside a roughly $2.8 million round. In December 2023, it invested another $325 thousand. At the end of 2024 and the beginning of 2025, it added a further $400 thousand in a round of about $1.5 million. At the end of 2025, Teuza invested another $250 thousand in a roughly $3 million round, and after the balance sheet, in early 2026, another $250 thousand went out in the same round.
On top of that, an additional capital layer remains open. From the late 2024 and early 2025 round, Teuza still holds an option to invest another $400 thousand on the same terms through March 31, 2027. So even after the $250 thousand that was already invested in early 2026, Nano Cell is still not out of the capital-demand zone. One more funding decision is still sitting on the table.
There is also one positive point that should not be erased. The round at the end of 2025 was not done only with existing shareholders. It also included new investors. That matters because it shows Nano Cell is not being supported only by an internal Teuza check. Even so, it does not solve the main problem. When an asset relies repeatedly on follow-on rounds, the market does not only ask whether fresh capital came in. It asks whether that capital is buying real commercial progress, or just more time.
Commercialization Still Does Not Carry the Valuation on Its Own
This is exactly where Nano Cell currently looks more like a funding story than a proven commercialization story. The company develops conductive ink and paste based on silver and copper, and its current main focus is solar. At the same time, it markets ink for additional applications, including printing on ceramics and on glass for the automotive industry. It has also started using its technology to create conductive paste that is better suited to mass production in solar. That is a logical direction, but in 2025 it still did not translate into sales strong enough to support the higher mark on their own.
Nano Cell's sales fell in 2025 to $265 thousand, down from $1.124 million in 2024. That is a decline of about 76%. Over the same period, the fair value of Teuza's holding in Nano Cell rose from $2.413 million to $2.913 million, an increase of about 21%. That gap is exactly the point a reader can miss on a first pass. The higher valuation did not come with clearer commercial proof. On the contrary, the sales line moved sharply lower.
This does not prove the valuation is wrong. At this stage, revenue can be lumpy, especially when a company is shifting application focus and moving toward a heavier industrial channel. But it is a clear reason to read the higher mark with more caution. As of the end of 2025, the increase rests more on the fact that investors were willing to fund the company on those terms than on the fact that Nano Cell had already shown stable enough commercial traction to materially reduce risk.
That makes 2026 a proof year. If the year brings repeat orders, industrial customers, or a sharp recovery in sales, the 2024 to 2026 follow-on rounds can still be read as a reasonable bridge to commercialization. If the next period ends mainly with another round and another mark, the reading changes. Then Nano Cell looks less like an asset that is maturing and more like a position that requires ongoing maintenance.
Where the Asset Ends and the Funding Line Begins
The most important layer is the distinction between three different numbers. The first is $2.913 million, the fair value that enters Teuza's portfolio at the end of 2025. The second is $2.829 million, the direct cash Teuza had invested in Nano Cell through the balance-sheet date. After the additional investment made in early 2026, that number already rose to $3.079 million, and if the remaining option through March 2027 is exercised it would reach $3.479 million. The third number is $6.472 million, the cumulative capital that the portfolio table attributes to this position.
The last number is the most telling, because it is a reminder that Nano Cell is not a fresh story inside the portfolio. Before the 2017 deal, Teuza held DigiFlex and had invested about $3.6 million there. In the sale to Nano Cell, all DigiFlex shareholders together received 25% of Nano Cell on a fully diluted basis, and Teuza also added another $106 thousand in Nano Cell shares and options. That is why Nano Cell now looks like an old position with a long capital memory, not like a new investment that suddenly received a fresh label.
| Layer | Amount | Meaning |
|---|---|---|
| Fair value of the holding at year-end 2025 | $2.913 million | The number that reaches the accounts |
| Direct investment in Nano Cell through December 31, 2025 | $2.829 million | Cash directly injected into the company through the balance sheet |
| Direct investment after the early 2026 follow-on | $3.079 million | The threshold that already exists after year-end |
| Open option through March 31, 2027 | $400 thousand | More capital that could still go out |
| Cumulative capital tied to the position | $6.472 million | The broader number showing how much time and money are already tied to Nano Cell |
What follows from this? On one hand, Nano Cell is no longer a footnote. It is almost the largest holding in the portfolio, and it sits on an addressable market that sounds much bigger than its current numbers. On the other hand, right now it is still not an asset that eases Teuza's cash burden. It is still part of that burden. As long as the mark rises together with follow-on injections, and as long as sales do not move back toward a level that economically supports the story, Nano Cell stays in the middle: a holding with real upside, but also a soft funding line that keeps demanding attention and capital.
The Bottom Line
Nano Cell has already crossed the line beyond which it can be described as a side item in Teuza's portfolio. At a fair value of $2.913 million, it has almost matched Tyto and become the second anchor in the story. But that is exactly where the problem begins: this mark currently sits on a path where commercialization has not yet delivered enough proof, while the follow-on rounds have already delivered a very real capital demand.
So the right read on Nano Cell today is not "here is another asset that appreciated." The more accurate reading is that Nano Cell has become a capital-allocation test. If 2026 brings real commercial proof, the 2024 to 2026 rounds may later look like a reasonable bridge. If not, it will become clear that Teuza did not just hold Nano Cell. It kept serving as a repeat funding source for it.
The thesis now is simple: Nano Cell is already too large to be treated as a footnote, but it is still not clean enough to be called a self-funding asset.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.